Effect [qlco]
moxonidine [orch, phsu]
plasma lipid [lbpr]
Profile [lbpr]
Subclass [clas]
distribution [idcn]
moxonidine [orch, phsu]
New [tmco]
Antihypertensive agent [phsu]
Mechanism [ftcn]
Action [ftcn]
APPEAR [qlco]
To [qlco]
Specific [qlco]
Stimulation [topp]
Imidazoline Receptors [aapp, rcpt]
Inhibition [menp]
activity [dora]
Central [spco]
Peripheral Nervous System [bdsy]
Drug [phsu]
To [qlco]
plasma lipid [lbpr]
Parameters [fndg]
Data [idcn]
effects [qlco]
moxonidine [orch, phsu]
Low density lipoprotein [aapp, bacs, lipd]
Subclass [clas]
Pattern [spco]
Oxidation [moft]
Susceptibility [clna]
Known [qlco]
To [qlco]
Play [dora]
Prominent [qlco]
Role [socb]
pathogenesis [ftcn]
Atherosclerosis [dsyn]
Present [qnco]
Study [mnob]
influential [idcn]
moxonidine [orch, phsu]
Subspecies [cnce]
Profile [lbpr]
Susceptibility [clna]
Copper [bacs, elii, phsu]
Induced [ftcn]
Oxidative [ftcn]
Modification [ftcn]
hypertensive [fndg]
Patients [podg]
Men [popg]
Women [popg]
Aged [orga]
moxonidine [orch, phsu]
Administered [ftcn]
Dose [qnco]
mg% [qnco]
Daily [tmco]
weeks [tmco]
Decrease [qlco]
Systolic [tmco]
Diastolic blood pressure [clna]
mmHg [qnco]
P NOS [aapp, imft]
mmHg [qnco]
P NOS [aapp, imft]
Change [ftcn]
plasma lipid [lbpr]
Profile [lbpr]
Observed [ftcn]
moxonidine [orch, phsu]
Administration [ocac]
Change [ftcn]
Susceptibility [clna]
subclasses [clas]
Copper [bacs, elii, phsu]
Induced [ftcn]
Oxidative [ftcn]
Modification [ftcn]
Drug Therapy [topp]
Not [ftcn]
Change [ftcn]
Phenotype [orga]
Mass [fndg]
Composition [clna]
Three [qnco]
conclude [bodm, orch]
Anti-Hypertensive Drugs [phsu]
Beta-Blockers [phsu]
Expression [topp]
Atherogenesis [patf]
Lipoprotein pattern [clna]
Subclass [clas]
moxonidine [orch, phsu]
Not [ftcn]
Affect [menp]
plasma lipid [lbpr]
Parameters [fndg]
Lipoprotein [aapp, bacs]
Composition [clna]
